pmid	doi	year	title	Hugo_Symbol
35301414	10.1038/s41379-022-01022-w	2022	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.	VAV1
35326399	10.3390/cells11060949	2022	Vav1 Promotes B-Cell Lymphoma Development.	VAV1
35443168	10.1016/j.celrep.2022.110695	2022	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.	VAV1
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	VAV1
35954378	10.3390/cancers14153716	2022	Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma.	VAV1
32606318	10.1038/s41375-020-0937-3	2021	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.	VAV1
34147695	10.1016/j.jmoldx.2021.04.013	2021	Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.	VAV1
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	VAV1
34417435	10.1038/s41392-021-00730-0	2021	BCL9 regulates CD226 and CD96 checkpoints in CD8<sup>+</sup> T cells to improve PD-1 response in cancer.	VAV1
34617326	10.15252/embj.2021108125	2021	Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.	VAV1
29313423	10.1080/21541248.2018.1423851	2020	Rho guanosine nucleotide exchange factors are not such bad guys after all in cancer<sup>a</sup>.	VAV1
31859368	10.1002/path.5376	2020	Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.	VAV1
32107212	10.1158/0008-5472.CAN-19-2787	2020	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma.	VAV1
32992343	10.1182/blood.2020006513	2020	VAV1 mutations contribute to development of T-cell neoplasms in mice.	VAV1
27898263	10.1080/21541248.2016.1263718	2019	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.	VAV1
30833082	10.1016/j.bbrc.2019.02.108	2019	The interaction between Vav1 and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the expression of Bim.	VAV1
28832024	10.1038/leu.2017.273	2018	Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.	VAV1
29200404	10.1172/JCI94509	2018	STAT5BN642H is a driver mutation for T cell neoplasia.	VAV1
29682742	10.1111/eci.12939	2018	Rac-GTPases and Rac-GEFs in neutrophil adhesion, migration and recruitment.	VAV1
30250888	10.1080/23723556.2018.1432257	2018	An unexpected tumor suppressor role for VAV1<sup>a</sup>.	VAV1
28062691	10.1073/pnas.1608839114	2017	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.	VAV1
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	VAV1
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	VAV1
29136506	10.1016/j.ccell.2017.10.004	2017	A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.	VAV1
27169444	10.11406/rinketsu.57.417	2016	[Genetic landscape of adult T-cell leukemia/lymphoma].	VAV1
27297792	10.1182/blood-2016-03-707141	2016	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.	VAV1
27669408	10.1371/journal.pone.0163011	2016	Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.	VAV1
26338970	10.18632/oncotarget.5009	2015	Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.	VAV1
26437031	10.1038/ng.3415	2015	Integrated molecular analysis of adult T cell leukemia/lymphoma.	VAV1
24501217	10.1182/blood-2013-08-523563	2014	Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.	VAV1
24534189	10.1084/jem.20131424	2014	Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.	VAV1
23757206	10.1016/j.bmc.2013.05.021	2013	RNA-aptamers that modulate the RhoGEF activity of Tiam1.	VAV1
22432082		2012	Vav1 in hematologic neoplasms, a mini review.	VAV1
22683124	10.1016/j.immuni.2012.03.023	2012	The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells.	VAV1
22692505	10.1182/blood-2011-06-361709	2012	Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.	VAV1
22717125	10.1016/j.ejcb.2012.04.006	2012	Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.	VAV1
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	VAV1
20007546	10.1182/blood-2009-04-216184	2010	Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.	VAV1
20155735	10.1002/hon.935	2010	Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.	VAV1
20011522	10.1371/journal.pone.0008229	2009	The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.	VAV1
18227156	10.1128/MCB.01505-07	2008	T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.	VAV1
18974134	10.1158/0008-5472.CAN-08-2568	2008	The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.	VAV1
16289966	10.1016/j.cellsig.2005.10.001	2006	Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.	VAV1
15345594	10.1182/blood-2003-08-2965	2005	The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor.	VAV1
15661896	10.4049/jimmunol.174.3.1385	2005	Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton.	VAV1
15661906	10.4049/jimmunol.174.3.1472	2005	Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.	VAV1
15964830	10.1128/MCB.25.13.5777-5785.2005	2005	Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.	VAV1
14630790	10.1182/blood-2003-07-2469	2004	VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.	VAV1
14673152	10.1128/MCB.24.1.164-171.2003	2004	CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1.	VAV1
12848851	10.1046/j.0818-9641.2003.01172.x	2003	Knockout B lymphoma cell lines as biochemical tools to explore multiple signalling pathways.	VAV1
14586401	10.1038/sj.onc.1207048	2003	Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.	VAV1
11846804	10.1046/j.0014-2956.2001.02741.x	2002	Transient activation of the c-Jun N-terminal kinase (JNK) activity by ligation of the tetraspan CD53 antigen in different cell types.	VAV1
12353912	10.1385/MB:22:1:025	2002	Functional cloning using pFB retroviral cDNA expression libraries.	VAV1
10232389	10.1016/s0165-2478(98)00142-4	1999	Apoptosis of thymic lymphoma clones by thymic epithelial cells: a putative model for 'death by neglect'.	VAV1
9886379		1999	Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway.	VAV1
10221598	10.1385/ENDO:9:3:313	1998	Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells.	VAV1
9040011	10.1093/intimm/9.2.291	1997	Targets of p56(lck) activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway.	VAV1
9168816	10.1006/excr.1997.3535	1997	Expression of the vav oncogene in somatic cell hybrids.	VAV1
9178638	10.1006/cimm.1997.1102	1997	CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.	VAV1
9341187	10.1074/jbc.272.43.27362	1997	Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cgamma, Grb2, and Vav after B cell antigen receptor activation.	VAV1
8632004	10.1074/jbc.271.7.3856	1996	The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.	VAV1
7508909		1994	Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells.	VAV1
7689723		1993	Selective association of the p59fyn tyrosine kinase with murine T lymphoma membrane phosphoproteins.	VAV1
7690544	10.1042/bj2940339	1993	Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck.	VAV1
